Skip to main content

Table 4 Pathological characteristics of patients with NLSLNM and LSLNM

From: Is lobe specific lymph node dissection adequate for cN0–1 non-small cell lung cancer?

VariablesNLSLNM (n = 129)LSLNM (n = 230)P value
Anatomical type  0.168
 Central31 (24.0%)71 (30.9%) 
 Peripheral98 (76.0%)159 (69.1%) 
Histology  0.022
 Adenocarcinoma103 (79.8%)161 (70.0%) 
 SCC14 (10.9%)52 (22.6%) 
 Others12 (9.3%)17 (7.4%) 
Cell differentiation  0.480
 Well-moderate3 (2.3%)2 (0.9%) 
 Moderate25 (19.4%)56 (24.3%) 
 Moderate-poor62 (48.1%)111 (48.3%) 
 Poor33 (25.6%)52 (22.6%) 
 NAa6 (4.7%)9 (3.9%) 
Pathological T stage  0.886
 T1a1 (0.8%)2 (0.9%) 
 T1b17 (13.2%)31 (13.5%) 
 T1c24 (18.6%)33 (14.5%) 
 T2a54 (41.9%)112 (48.7%) 
 T2b17 (13.2%)24 (10.4%) 
 T312 (9.3%)21 (9.1%) 
 T44 (3.1%)7 (3.0%) 
Pathological TNM stage  0.853
 IIIA113 (87.6%)203 (88.3%) 
 IIIB16 (12.4%)27 (11.7%) 
Tumor sizeb, cm  0.830
 Median (range)3.0 (0.8–8.0)3.0 (0.9–10.0) 
 Visceral pleural invasion51 (39.5%)73 (31.7%)0.136
 Lymphovascular invasion30 (23.3%)44 (19.1%)0.354
 Skip N2 metastasis25 (19.4%)65 (28.3%)0.062
N1 involvement
 1051 (39.5%)61 (26.5%)0.011
 1147 (36.4%)48 (20.9%)0.001
 1283 (64.3%)124 (53.9%)0.055
  1. NLSLNM non-lobe specific lymph node metastasis; LSLNM lobe specific lymph node metastasis; SCC Squamous cell carcinoma; NA not available
  2. a Cases that were not available, and were hence excluded when calculating the p-value
  3. b Tumor size was defined as the maximum diameter of the pathological specimens
  4. Values are N (percentage) unless otherwise specified